All posts

HIVE Blockchain’s future looks precarious, this analyst says

Investors interested in the cryptocurrency space need look no further than mining company HIVE Blockchain (HIVE Blockchain Stock Quote, Chart TSXV:HIVE) to get a glimpse at what falling prices for bitcoin and ethereum can do to a company in the space, says Horizons ETFs analyst Brooke Thackray, who cautions that with bitcoin edging close to a crucial $6,000 support level, heading any lower could spell big trouble for HIVE.

Bitcoin is about to celebrate a 10-year anniversary of sorts, as it was on October 31, 2008, that someone (or someones —the identity remains a mystery) by the name of Satoshi Nakamoto published the paper, “Bitcoin: A Peer-to-Peer Electronic Cash System” that jumpstarted the cryptographic process which resulted in bitcoin’s launch just a few months later.

But while bitcoin’s rise and fall over the past year and a half is well-known, what the future holds for it and its crypto-cousins is unclear. Ethereum, HIVE Blockchain’s central mining focus, recently experienced a hitch in its development, as the upgrade called Constantinople had to be delayed until January, 2019. Like bitcoin, ethereum has seen both tremendous highs and now humbling lows, with the currency now priced at $202.00, a low not seen since July, 2017. (All figures in US dollars unless noted otherwise.)

The downward plunge in cryptocurrency prices has clearly impacted the fortunes of mining companies like HIVE, says Thackray, who spoke to BNN Bloomberg.

HIVE Blockchain stock chart mirrors bitcoin chart

“If you take a look at the graph for HIVE you can see that it looks very similar to bitcoin,” he says. “On bitcoin’s [chart], it’s really what we call a descending triangle in technical terms: each of the highs is lower going all the way across and we’re at support at about US$6,000. If we do see it break below that support, we would see negative repercussions where it actually might go much lower than that. And that would reflect back onto HIVE as well.”

HIVE, which began trading in September, 2017, saw its share price rise from C$0.74 to as high as C$6.75 just two months later. The decline was almost as swift, however, with the stock currently trading at C$0.60.

HIVE last reported earnings on August 29, showing Q1/2019 income from currency mining of $10.6 million and an adjusted EBITDA of $3.5 million.

Tagged with: hive
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Trulieve Cannabis is a buy, Beacon says

Trulieve Cannabis (Trulieve Cannabis Stock Quote, Chart, News, Analysts, Financials CSE:TRUL) delivered a strong start to fiscal 2025, beating high-end… [Read More]

48 minutes ago

Green Thumb Industries should be a core holding for cannabis investors, analyst says

Green Thumb Industries (Green Thumb Industries Stock Quote, Chart, News, Analysts, Financials CSE:GTII) delivered a steady first quarter and remains… [Read More]

1 hour ago

5N Plus just delivered an “exceptional” quarter, this analyst says

5N Plus (5N Plus Stock Quote, Chart, News, Analysts, Financials TSX:VNP) blew past expectations in the first quarter of 2025,… [Read More]

17 hours ago

Kinaxis is still undervalued, ATB Capital says

Kinaxis (Kinaxis Stock Quote, Chart, News, Analysts, Financials TSXV:KXS) delivered first-quarter results that met expectations, with record adjusted EBITDA and… [Read More]

17 hours ago

Spectral Medical is “fundamentally undervalued”, Paradigm says

Paradigm Capital analyst Scott McAuley is maintaining a "Buy" rating and $2.30 target on Spectral Medical (Spectral Medical Stock Quote,… [Read More]

22 hours ago

Is Ballard Power a buy?

Ballard Power’s (Ballard Power Stock Quote, Chart, News, Analysts, Financials NASDAQ:BLDP) disappointing Q1 2025 results prompted Roth Capital Partners analyst… [Read More]

22 hours ago